Literature DB >> 33922413

Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review.

Rosa María Girón Moreno1, Marta García-Clemente2, Layla Diab-Cáceres3, Adrián Martínez-Vergara4, Miguel Ángel Martínez-García5, Rosa Mar Gómez-Punter1.   

Abstract

Cystic fibrosis (CF) is a genetic disease that causes absence or dysfunction of a protein named transmembrane conductance regulatory protein (CFTR) that works as an anion channel. As a result, the secretions of the organs where CFTR is expressed are very viscous, so their functionality is altered. The main cause of morbidity is due to the involvement of the respiratory system as a result of recurrent respiratory infections by different pathogens. In recent decades, survival has been increasing, rising by around age 50. This is due to the monitoring of patients in multidisciplinary units, early diagnosis with neonatal screening, and advances in treatments. In this chapter, we will approach the different therapies used in CF for the treatment of symptoms, obstruction, inflammation, and infection. Moreover, we will discuss specific and personalized treatments to correct the defective gene and repair the altered protein CFTR. The obstacle for personalized CF treatment is to predict the drug response of patients due to genetic complexity and heterogeneity of uncommon mutations.

Entities:  

Keywords:  CFTR modulator; RNA therapy; antibiotic; cystic fibrosis; editing gene; genetic therapy; inflammation; obstruction; treatment

Year:  2021        PMID: 33922413     DOI: 10.3390/antibiotics10050486

Source DB:  PubMed          Journal:  Antibiotics (Basel)        ISSN: 2079-6382


  222 in total

Review 1.  [Cystic fibrosis: consensus on the treatment of pneumothorax and massive hemoptysis and on the indications for lung transplantation].

Authors:  C Prados; L Máiz; C Antelo; F Baranda; J Blázquez; J M Borro; S Gartner; G Garzón; R Girón; J de Gracia; J Lago; R Lama; M T Martínez; A Moreno; C Oliveira; J Pérez Frías; A Solé; A Salcedo
Journal:  Arch Bronconeumol       Date:  2000 Jul-Aug       Impact factor: 4.872

2.  Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.

Authors:  Michael W Konstan; Patrick A Flume; Matthias Kappler; Raphaël Chiron; Mark Higgins; Florian Brockhaus; Jie Zhang; Gerhild Angyalosi; Ellie He; David E Geller
Journal:  J Cyst Fibros       Date:  2010-11-12       Impact factor: 5.482

Review 3.  Genotypes and phenotypes in cystic fibrosis and cystic fibrosis transmembrane regulator-related disorders.

Authors:  Cristina Bombieri; Manuela Seia; Carlo Castellani
Journal:  Semin Respir Crit Care Med       Date:  2015-03-31       Impact factor: 3.119

4.  Rescue of nonsense mutations by amlexanox in human cells.

Authors:  Sara Gonzalez-Hilarion; Terence Beghyn; Jieshuang Jia; Nadège Debreuck; Gonzague Berte; Kamel Mamchaoui; Vincent Mouly; Dieter C Gruenert; Benoit Déprez; Fabrice Lejeune
Journal:  Orphanet J Rare Dis       Date:  2012-08-31       Impact factor: 4.123

5.  Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX-02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers.

Authors:  Andi Leubitz; Anat Frydman-Marom; Neal Sharpe; John van Duzer; Kathleen C M Campbell; Frédéric Vanhoutte
Journal:  Clin Pharmacol Drug Dev       Date:  2019-01-16

6.  Applying Cystic Fibrosis Transmembrane Conductance Regulator Genetics and CFTR2 Data to Facilitate Diagnoses.

Authors:  Patrick R Sosnay; Danieli B Salinas; Terry B White; Clement L Ren; Philip M Farrell; Karen S Raraigh; Emmanuelle Girodon; Carlo Castellani
Journal:  J Pediatr       Date:  2017-02       Impact factor: 4.406

7.  Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.

Authors:  Jane C Davies; Claire E Wainwright; Gerard J Canny; Mark A Chilvers; Michelle S Howenstine; Anne Munck; Jochen G Mainz; Sally Rodriguez; Haihong Li; Karl Yen; Claudia L Ordoñez; Richard Ahrens
Journal:  Am J Respir Crit Care Med       Date:  2013-06-01       Impact factor: 21.405

Review 8.  A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect.

Authors:  Michael P Boyle; Kris De Boeck
Journal:  Lancet Respir Med       Date:  2013-01-30       Impact factor: 30.700

9.  Age-Dependent Progression in Lung Pathophysiology can be Prevented by Restoring Fatty Acid and Ceramide Imbalance in Cystic Fibrosis.

Authors:  Mina Youssef; Juan B De Sanctis; Juhi Shah; Daciana Catalina Dumut; Marian Hajduch; Basil J Petrof; Danuta Radzioch
Journal:  Lung       Date:  2020-04-18       Impact factor: 2.584

Review 10.  Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus.

Authors:  Harry Heijerman; Elsbeth Westerman; Steven Conway; Daan Touw; Gerd Döring
Journal:  J Cyst Fibros       Date:  2009-06-25       Impact factor: 5.482

View more
  3 in total

1.  In Vivo Activity of Metal Complexes Containing 1,10-Phenanthroline and 3,6,9-Trioxaundecanedioate Ligands against Pseudomonas aeruginosa Infection in Galleria mellonella Larvae.

Authors:  Megan O'Shaughnessy; Magdalena Piatek; Pauraic McCarron; Malachy McCann; Michael Devereux; Kevin Kavanagh; Orla Howe
Journal:  Biomedicines       Date:  2022-01-21

Review 2.  Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology.

Authors:  Simona Barone; Emilia Cassese; Antonella Ilenia Alfano; Margherita Brindisi; Vincenzo Summa
Journal:  J Med Chem       Date:  2022-02-11       Impact factor: 7.446

3.  A Shaving Proteomic Approach to Unveil Surface Proteins Modulation of Multi-Drug Resistant Pseudomonas aeruginosa Strains Isolated From Cystic Fibrosis Patients.

Authors:  Anna Lisa Montemari; Valeria Marzano; Nour Essa; Stefano Levi Mortera; Martina Rossitto; Simone Gardini; Laura Selan; Gianluca Vrenna; Andrea Onetti Muda; Lorenza Putignani; Ersilia Vita Fiscarelli
Journal:  Front Med (Lausanne)       Date:  2022-03-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.